Shareholder Alert: Ademi LLP investigates whether Silk Road Medical, Inc. has obtained a Fair Price for its Public Shareholders

MILWAUKEE, June 18, 2024 /PRNewswire/ -- Ademi LLP is investigating Silk Road Medical (Nasdaq: SILK) for possible breaches of fiduciary duty and other violations of law in its transaction with Boston Scientific.

Click here to learn how to join the https://www.ademilaw.com/case/silk-road-medical-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

In the transaction, Silk Road Medical shareholders will receive only $27.50 per share, reflecting an enterprise value of approximately $1.16 billion. The transaction agreement unreasonably limits competing transactions for Silk Road Medical by imposing a significant penalty if Silk Road Medical accepts a competing bid. Silk Road Medical insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Silk Road Medical's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Silk Road Medical common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/silk-road-medical-inc.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP